MWMichael Tzu Min Wang

Michael Tzu Min Wang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Michael Tzu Min Wang has a total of 196 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Pharmacological, Natural and Emerging Therapies for Meibomian Gland Dysfunction: A Review

    by Jordan M. Cooper, Ryan Mahmoud, Catherine J. Jennings, Kalika Bandamwar, Michael T. M. Wang, Jennifer P. Craig

    Meibomian gland dysfunction (MGD) is a leading cause of non-aqueous deficient dry eye disease. Meibomian glands are responsible for the production of meibum, a lipid-rich secretion that coats the surface of the tear film, inhibiting evaporation of the underlying aqueous tear fluid. MGD can arise due to numerous extrinsic and intrinsic factors that drive changes in meibum quality or obstruction of gland orifices and can result in tear film instability, hyperosmolarity, epithelial damage and downstream ocular surface inflammation. Despite the high disease prevalence, management is not standardised, with a wide range of pharmacological and naturally derived therapies available. Potential pharmacological agents include anti-inflammatories (antibiotics, immunosuppressants and topical integrin antagonists), perfluorohexyloctane and topical aqueous secretagogues. Natural therapies that may offer suitable long-term solutions include oral dietary supplements (polyunsaturated fatty acids, astaxanthin, bilberry, Chinese herbal formulations and Korean red ginseng) and naturally derived topical formulations (castor oil, manuka honey, tea tree oil, coenzyme Q10 and green tea extract). The rising prevalence of MGD has led to the development of several novel therapeutic strategies, expanding the range of management options available to clinicians. A thorough examination should precede the initiation of treatment to identify underlying pathophysiology and guide targeted interventions. Treatment efficacy, duration and safety profiles must also be considered.


  • Open Access

    Non-invasive convective head cooling during stroke thrombectomy: A prospective multi-center feasibility trial

    by William K Diprose, Catherine Veilleux, Mohammed Almekhlafi, Alec Beresford, Kaustubha Ghate, Davina McAllister, Michael T M Wang, Jessica Wiles, Douglas Campbell, P Alan Barber

    Introduction: Non-invasive convective head cooling is a promising putative neuroprotective therapy for ischemic stroke patients as it may portably, non-invasively, and selectively cool the ischemic penumbra. We aimed to investigate the feasibility of utilizing non-invasive convective head cooling in ischemic stroke patients before and during endovascular thrombectomy (EVT). Patients and methods: We conducted a multi-center, prospective, non-randomized, open-label trial at two comprehensive stroke centers in ischemic stroke patients where EVT was planned. Patients were assessed for eligibility in the emergency department (ED) and had a cooling cap fitted that circulated coolant between −5°C and 0°C until EVT completion. The primary feasibility endpoint was adherence, defined as tolerating cooling for ⩾50% of the time from cooling cap application until EVT completion. Results: Between July and November 2024, 40 EVT patients (19 (47.5%) female, mean ± SD age 71.6 ± 12.6 years) underwent a median (IQR) duration of convective head cooling of 86 (58–106) min. Thirty-nine (97.5%) participants met the primary feasibility endpoint. The enrollment rate was five participants per site per month. Median (IQR) time from comprehensive stroke center arrival to cooling start was 10 (5–51) min. Thirty-two (80%) patients received general anesthesia. eTICI 2b-3 reperfusion was achieved in 38 (95.0%) participants. Median (IQR) 24-h infarct volume was 14.3 (5.5–29.1) mL. Median (IQR) 3-month modified Rankin Scale score was 2 (1–5). Three-month mortality occurred in 8/38 (21.1%) participants. Nine serious adverse events occurred in 8 (20.0%) participants, none of which were attributed to head cooling. Conclusions: Convective head cooling is feasible in patients undergoing EVT and warrants further investigation in larger randomized controlled trials.


  • Non-invasive convective head cooling during stroke thrombectomy: A prospective multi-center feasibility trial

    by William K Diprose, Catherine Veilleux, Mohammed Almekhlafi, Alec Beresford, Kaustubha Ghate, Davina McAllister, Michael Tm Wang, Jessica Wiles, Douglas Campbell, P Alan Barber

    Introduction: Non-invasive convective head cooling is a promising putative neuroprotective therapy for ischemic stroke patients as it may portably, non-invasively, and selectively cool the ischemic penumbra. We aimed to investigate the feasibility of utilizing non-invasive convective head cooling in ischemic stroke patients before and during endovascular thrombectomy (EVT). Patients and methods: We conducted a multi-center, prospective, non-randomized, open-label trial at two comprehensive stroke centers in ischemic stroke patients where EVT was planned. Patients were assessed for eligibility in the emergency department (ED) and had a cooling cap fitted that circulated coolant between −5°C and 0°C until EVT completion. The primary feasibility endpoint was adherence, defined as tolerating cooling for ⩾50% of the time from cooling cap application until EVT completion. Results: Between July and November 2024, 40 EVT patients (19 (47.5%) female, mean ± SD age 71.6 ± 12.6 years) underwent a median (IQR) duration of convective head cooling of 86 (58–106) min. Thirty-nine (97.5%) participants met the primary feasibility endpoint. The enrollment rate was five participants per site per month. Median (IQR) time from comprehensive stroke center arrival to cooling start was 10 (5–51) min. Thirty-two (80%) patients received general anesthesia. eTICI 2b-3 reperfusion was achieved in 38 (95.0%) participants. Median (IQR) 24-h infarct volume was 14.3 (5.5–29.1) mL. Median (IQR) 3-month modified Rankin Scale score was 2 (1–5). Three-month mortality occurred in 8/38 (21.1%) participants. Nine serious adverse events occurred in 8 (20.0%) participants, none of which were attributed to head cooling. Conclusions: Convective head cooling is feasible in patients undergoing EVT and warrants further investigation in larger randomized controlled trials.


  • Diagnostic criteria for meibomian gland dysfunction: A prospective registry-based external validation analysis

    by Michael T.M. Wang, Jordan M. Cooper, Catherine J. Jennings, Barry Power, James S. Wolffsohn, Jennifer P. Craig


  • Repeatability of tear film lipid layer interferometry measurements: A randomized, crossover study

    by Michael T. M. MBChB Wang, Stuti L. PhD Misra, Akilesh PhD Gokul, Ji Soo MBChB Kim, Andy D. MBChB Kim, Ally L. PhD Xue, Andrea Cruzat, Jennifer P. PhD Craig

    SIGNIFICANCE: Tear film lipid layer interferometry is one of the most sensitive diagnostic markers for evaporative dry eye disease. However, the dynamic structure breaks up and reforms rapidly during each blink cycle, and it remains yet to be established whether there may be significant intrasessional, diurnal, or day‐to‐day variability. PURPOSE: This study aimed to assess intrasession repeatability, diurnal intravisit and day‐to‐day intervisit reproducibility of qualitative tear film lipid layer interferometry grading obtained from the Keratograph 5M (Oculus Optikgeräte GmbH, Wetzlar, Germany), and automated quantitative layer thickness measurements obtained from the TearScience LipiView II Ocular Surface Interferometer (Johnson & Johnson Vision, Milpitas, CA), in community residents, not stratified by dry eye or blepharitis status. METHODS: Forty community residents (24 women, 16 men; age mean ± standard deviation, 36 ± 14 years) were recruited in an investigator‐masked, randomized, crossover study. Participants attended two sessions 6 hours apart on the same day and a third session on a separate day. During each session, tear film lipid layer grading and thickness measurements were performed in triplicate, in a masked manner, with 10‐minute intervals between each measurement. RESULTS: There were no significant differences in lipid layer grading and thickness measurements in all pairwise intrasession, diurnal intravisit, and day‐to‐day intervisit comparisons (all p≥0.19), and positive correlations were observed in all cases (all pκ coefficients for intrasession repeatability and diurnal intravisit and day‐to‐day intervisit reproducibility of qualitative lipid layer grading ranged from 0.670 to 0.867. The test‐retest repeatability of quantitative lipid layer thickness measurements ranged from 4.5 to 11.7 nm, and the Bland‐Altman biases were within the order of 3 nm in all pairwise comparisons. The intraclass correlation coefficients for lipid layer thickness measurements exceeded 0.80 for all intrasession comparisons and were between 0.60 and 0.80 for all diurnal intravisit and day‐to‐day intervisit comparisons. CONCLUSIONS: Both qualitative grading and automated quantitative thickness measurements of tear film lipid layer interferometry demonstrated relatively favorable levels of intrasession repeatability and diurnal intravisit and day‐to‐day intervisit reproducibility. The study findings would support the use of either qualitative or quantitative measurement in clinical and research settings, as a reliable tool for assessing lipid layer interferometry.


  • Meibomian gland tortuosity, truncation, and dilation in paediatric dry eye disease: A multi-centre, investigator-masked, cross-sectional study

    by Michael T.M. Wang, James S. Wolffsohn, Ji Soo Kim, Sophie Speakman, Edward Pritchard, Barry Power, Jennifer P. Craig